Literature DB >> 20181595

Proteomic identification of binding partners for the brain metabolite lanthionine ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures.

Kenneth Hensley1, Alexandar Christov, Shekhar Kamat, X Cai Zhang, Kenneth W Jackson, Stephen Snow, Jan Post.   

Abstract

Lanthionine ketimine (LK) represents a poorly understood class of thioethers present in mammalian CNS. Previous work has indicated high-affinity interaction of LK with synaptosomal membrane protein(s), but neither LK binding partners nor specific bioactivities have been reported. In this study, LK was chemically synthesized and used as an affinity agent to capture binding partners from mammalian brain lysate. Liquid chromatography with electrospray ionization-mass spectrometry of electrophoretically separated, LK-bound proteins identified polypeptides implicated in axon remodeling or vesicle trafficking and diseases including Alzheimer's disease and schizophrenia: collapsin response mediator protein-2/dihydropyrimidinase-like protein-2 (CRMP2/DRP2/DPYSL2), myelin basic protein, and syntaxin-binding protein-1 (STXBP1/Munc-18). Also identified was the recently discovered glutathione-binding protein lanthionine synthetase-like protein-1. Functional consequences of LK:CRMP2 interactions were probed through immunoprecipitation studies using brain lysate wherein LK was found to increase CRMP2 coprecipitation with its partner neurofibromin-1 but decreased CRMP2 coprecipitation with beta-tubulin. Functional studies of NSC-34 motor neuron-like cells indicated that a cell-permeable LK-ester, LKE, was nontoxic and protective against oxidative challenge with H(2)O(2). LKE-treated NSC-34 cells significantly increased neurite number and length in a serum concentration-dependent manner, consistent with a CRMP2 interaction. Finally, LKE antagonized the activation of EOC-20 microglia by inflammogens. The results are discussed with reference to possible biochemical origins, paracrine functions, neurological significance, and pharmacological potential of lanthionyl compounds.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181595      PMCID: PMC2836831          DOI: 10.1523/JNEUROSCI.5247-09.2010

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  48 in total

1.  Professor Doriano Cavallini: a life for sulfur biochemistry.

Authors:  S Duprè
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

2.  Isolation of 2000-kDa complexes of N-methyl-D-aspartate receptor and postsynaptic density 95 from mouse brain.

Authors:  H Husi; S G Grant
Journal:  J Neurochem       Date:  2001-04       Impact factor: 5.372

3.  Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD.

Authors:  Tanea T Reed; William M Pierce; William R Markesbery; D Allan Butterfield
Journal:  Brain Res       Date:  2009-04-15       Impact factor: 3.252

4.  LANCL2 is necessary for abscisic acid binding and signaling in human granulocytes and in rat insulinoma cells.

Authors:  Laura Sturla; Chiara Fresia; Lucrezia Guida; Santina Bruzzone; Sonia Scarfì; Cesare Usai; Floriana Fruscione; Mirko Magnone; Enrico Millo; Giovanna Basile; Alessia Grozio; Emanuela Jacchetti; Marcello Allegretti; Antonio De Flora; Elena Zocchi
Journal:  J Biol Chem       Date:  2009-08-10       Impact factor: 5.157

5.  Neuroprotective potency of kynurenic acid against excitotoxicity.

Authors:  J Urenjak; T P Obrenovitch
Journal:  Neuroreport       Date:  2000-04-27       Impact factor: 1.837

6.  Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse.

Authors:  N Arimura; N Inagaki; K Chihara; C Ménager; N Nakamura; M Amano; A Iwamatsu; Y Goshima; K Kaibuchi
Journal:  J Biol Chem       Date:  2000-08-04       Impact factor: 5.157

7.  A missense mutation in kynurenine aminotransferase-1 in spontaneously hypertensive rats.

Authors:  John B J Kwok; Ranjna Kapoor; Takanari Gotoda; Yasuhiko Iwamoto; Yoko Iizuka; Nobuhiro Yamada; Kim E Isaacs; Virag V Kushwaha; W Bret Church; Peter R Schofield; Vimal Kapoor
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

8.  Proteomic analysis reveals novel binding partners of dysbindin, a schizophrenia-related protein.

Authors:  Takao Hikita; Shinichiro Taya; Yasutaka Fujino; Setsuko Taneichi-Kuroda; Kanae Ohta; Daisuke Tsuboi; Tomoyasu Shinoda; Keisuke Kuroda; Yusuke Funahashi; Junko Uraguchi-Asaki; Ryota Hashimoto; Kozo Kaibuchi
Journal:  J Neurochem       Date:  2009-07-01       Impact factor: 5.372

9.  Regional distribution of homocysteine in the mammalian brain.

Authors:  O J Broch; P M Ueland
Journal:  J Neurochem       Date:  1984-12       Impact factor: 5.372

10.  Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression.

Authors:  A T Behan; C Byrne; M J Dunn; G Cagney; D R Cotter
Journal:  Mol Psychiatry       Date:  2008-02-12       Impact factor: 15.992

View more
  34 in total

Review 1.  Collapsin response mediator protein-2: an emerging pathologic feature and therapeutic target for neurodisease indications.

Authors:  Kenneth Hensley; Kalina Venkova; Alexandar Christov; William Gunning; Joshua Park
Journal:  Mol Neurobiol       Date:  2011-01-28       Impact factor: 5.590

Review 2.  Nitrone-based therapeutics for neurodegenerative diseases: their use alone or in combination with lanthionines.

Authors:  Robert A Floyd; Hugo C Castro Faria Neto; Guy A Zimmerman; Kenneth Hensley; Rheal A Towner
Journal:  Free Radic Biol Med       Date:  2013-02-16       Impact factor: 7.376

3.  Comparative proteomic analyses of the parietal lobe from rhesus monkeys fed a high-fat/sugar diet with and without resveratrol supplementation, relative to a healthy diet: Insights into the roles of unhealthy diets and resveratrol on function.

Authors:  Aaron M Swomley; Judy C Triplett; Jeriel T Keeney; Govind Warrier; Kevin J Pearson; Julie A Mattison; Rafael de Cabo; Jian Cai; Jon B Klein; D Allan Butterfield
Journal:  J Nutr Biochem       Date:  2016-10-13       Impact factor: 6.048

4.  Lanthionine synthetase C-like protein 1 interacts with and inhibits cystathionine β-synthase: a target for neuronal antioxidant defense.

Authors:  Wei-xia Zhong; Yu-bin Wang; Lin Peng; Xue-zhen Ge; Jie Zhang; Shuang-shuang Liu; Xiang-nan Zhang; Zheng-hao Xu; Zhong Chen; Jian-hong Luo
Journal:  J Biol Chem       Date:  2012-08-13       Impact factor: 5.157

5.  A derivative of the CRMP2 binding compound lanthionine ketimine provides neuroprotection in a mouse model of cerebral ischemia.

Authors:  Shadia E Nada; Jatin Tulsulkar; Aparna Raghavan; Kenneth Hensley; Zahoor A Shah
Journal:  Neurochem Int       Date:  2012-10-02       Impact factor: 3.921

6.  Multiple-step, one-pot synthesis of 2-substituted-3-phosphono-1-thia-4-aza-2-cyclohexene-5-carboxylates and their corresponding ethyl esters.

Authors:  Dunxin Shen; Kenneth Hensley; Travis T Denton
Journal:  Bioorg Med Chem Lett       Date:  2018-02-01       Impact factor: 2.823

Review 7.  Lysine metabolism in mammalian brain: an update on the importance of recent discoveries.

Authors:  André Hallen; Joanne F Jamie; Arthur J L Cooper
Journal:  Amino Acids       Date:  2013-09-17       Impact factor: 3.520

Review 8.  Imine reductases: a comparison of glutamate dehydrogenase to ketimine reductases in the brain.

Authors:  André Hallen; Joanne F Jamie; Arthur J L Cooper
Journal:  Neurochem Res       Date:  2013-01-12       Impact factor: 3.996

Review 9.  Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain.

Authors:  Rukhsana Sultana; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2012-10-05       Impact factor: 7.376

Review 10.  CRMPs Function in Neurons and Glial Cells: Potential Therapeutic Targets for Neurodegenerative Diseases and CNS Injury.

Authors:  Jun Nagai; Rina Baba; Toshio Ohshima
Journal:  Mol Neurobiol       Date:  2016-06-23       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.